Effective RSV treatment still lacking despite recent breakthroughs in prophylaxis
National Respiratory Syncytial Virus (RSV) Awareness Month is observed each October in the USA, to align with the start of RSV season.
The campaign highlights the global health and economic burden of RSV, which poses serious risks to infants, older adults, and immunocompromised individuals, and encourages the public to engage in preventative measures, including immunization. Yet, despite recent breakthroughs in prophylaxis, treatment options for this common infection remain scarce, says pharma analytics company GlobalData.
According to GlobalData forecasts, the US market alone will see sales of $2.7 billion in 2025, driven by the advances that have rapidly reshaped the RSV prophylaxis landscape. The country has seen the approval of multiple RSV prophylaxis products in the past two years, following decades of limited progress.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze